| 14th week of 2010 patent applcation highlights part 32 |
| Patent application number | Title | Published |
|---|
| 20100086517 | Enhancement of B cell proliferation by IL-15 - Compositions and methods for modulating the growth, proliferation, and/or differentiation of B-cells in the germinal center are disclosed, and include use of IL-15 inhibitors, antagonists, and agonists. The compositions and methods find use in treating B-cell-related disorders, including neoplasms of the B-cell lineage. | 2010-04-08 |
| 20100086518 | TREATMENT OF MELANOMA - Methods of treating melanoma include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The compound, tautomer, salt of the compound, salt of the tautomer, or mixture thereof may be used to prepare medicaments for treating metastatic cancer. The variable A has the values defined herein. | 2010-04-08 |
| 20100086519 | Treatment of Hepatitis C Infection With Metalloporphyrins - The present invention is directed to the treatment of hepatitis C infection with a metalloporphyrin. In particular, the present invention is based on the discovery that the NS5A protein plays a key role in HCV RNA replication by participating in polyprotein cleavage, interferon response and cellular signaling pathways. It has been found that metalloporphyrins, such as zinc porphyrins, induce post-translational down-regulation of HCV NS5A protein in an ubquitin-proteasome degradation pathway. That is, metalloporphyrins can be used to activate the ubiquitin-proteasomal pathway of NS5A protein catabolism. As a result, metalloporphyrins can be used to significantly suppress HCV viral replication in HCV infected cells. | 2010-04-08 |
| 20100086520 | Compositions, Kits and Uses For Protecting The Skin Against Pathogenic Microorganisms - Described are compositions and kits comprising: (i) microorganisms which are able to stimulate the growth of microorganisms of the resident skin microbial flora and which do not stimulate the growth of microorganisms of the transient pathogenic micro flora and (ii) microorganisms which are able to inhibit the growth of one or more microorganisms of the transient pathogenic skin micro flora and which do not inhibit the growth of microorganisms of the healthy normal resident skin micro flora, in order to protect the skin against pathogenic microorganisms and to treat skin diseases. The present invention also relates to uses of the above mentioned microorganisms and to methods for the production of compositions and kits comprising such microorganisms. | 2010-04-08 |
| 20100086521 | Means For Regulating The Cosmetic Appearance And/Or Health Of Human Keratinous Tissue - Regulating human keratinous tissue (e.g., skin, hair, and/or nails). More particularly, the invention relates to regulating the cosmetic appearance and/or health of human keratinous tissue by orally administering a dietary supplement comprising a probiotic to a human. In another aspect, the invention also relates to a method of marketing, an article of commerce, and a personal care kit. | 2010-04-08 |
| 20100086523 | METHOD FOR GENERATING PLURIPOTENT STEM CELLS - The present invention relates to a method for generating pluripotent stem cells and to pluripotent stem cells generated from human testis. | 2010-04-08 |
| 20100086524 | CELLULAR PREPARATIONS FOR USE AS A REVASCULARIZATION STIMULATING AGENT - The invention relates to a cellular preparation containing endothelial cell precursors (EPCs) and smooth muscular cell precursors (SMCs), as a combination product for simultaneous, separated or time-spread administration, used as a revascularisation stimulating agent. The invention also relates to the use of such a cellular preparation. | 2010-04-08 |
| 20100086525 | Compositions and Methods for Altering Pancreas or Liver Function - Methods for altering pancreatic and liver cell function are provided, wherein the compositions and methods are based on use of osteopontin or on altering the activity of osteopontin. | 2010-04-08 |
| 20100086526 | NUCLEIC ACID CONSTRUCTS AND METHODS FOR SPECIFIC SILENCING OF H19 - The present invention is directed to recombinant constructs and methods for treating pathological conditions associated with H19 expression, such as tumors characterized by up-regulated expression of H19 RNA. Specifically, the recombinant constructs of the invention comprise at least one nucleic acid sequence encoding a small interfering RNA (siRNA) molecule directed to H19, the nucleic acid sequence being operably linked to at least one H19-specific transcription-regulating sequence. Vectors comprising these constructs, pharmaceutical compositions comprising them and therapeutic methods of using same are also provided. | 2010-04-08 |
| 20100086527 | SYNBIOTIC TO IMPROVE GUT MICROBIOTA - The use of a probiotic strain of | 2010-04-08 |
| 20100086528 | NOVEL BACTERIA ISOLATED FROM FRESH HONEY OR THE HONEY PRODUCING TRACT OF HONEY BEES - The invention relates to new isolated | 2010-04-08 |
| 20100086529 | METHODS OF MAKING CONCENTRATED FIBRINOGEN- AND PLATELET-CONTAINING COMPOSITIONS - The present invention is drawn to methods of making concentrated fibrinogen- and platelet-containing compositions. The concentrated compositions can be produced by adding a sufficient amount of a fibrinogen precipitating agent, such as protamine or other similar acting agent(s), and a platelet aggregating agent, such as ADP or other similar acting agents(s), to a platelet/fibrinogen containing fluid to cause the fibrinogen to form a fibrinogen precipitate and the platelets to for platelet aggregations. The fibrinogen precipitate and the platelet aggregates are collected by a collection technique, such as filtration, settling, centrifugation, etc., and are solubilized and deaggregated, respectively, in a liquid vehicle to form a concentrated fibrinogen- and platelet-containing composition. The concentrated platelet and/or fibrinogen compositions can be incorporated into systems for making fibrin glues, hemostatic sealants, platelet rich wound healants, and other wound treating compositions. | 2010-04-08 |
| 20100086530 | Cancer-tumor necrosis by artery nutrient-oxygen blocking - This is a new, novel, natural, relatively non-invasive and non-toxic method for the shrinkage and necrosis of cancerous cells, tumors, glands, organs, metastases processes or unwanted growths in human or animal patients. A patient's or other donor's blood is aged and processed which results in the loss of its blood vessel dilating component, nitric oxide. In addition to the loss of the vessel dilating component the other components of the blood become stiffer, stickier and sludgier. This processed blood is to then be directed by injection or catheter into the newly formed, fine, fragile, deranged and disorganized micro-capillaries of the patients cancerous tumors or unwanted growths or into the arteries that feed them nutrients and oxygen. The processed blood blocks, clogs or clots these super-fine micro-vessels and their wasteline pathways thereby causing the cancerous tumors or unwanted growths to shrink and die. The processed, aged or modified blood can also be used in combination with a blood separating hemapheresic means which can separate out the nitric oxide and/or any other components which would make the blocking blood more fluid or less viscous and can also be used immediately without further aging. In addition, the hemapheresic means can also separate other blocking components of the blood such as artery plaque building agents which together with the nitric oxide depleted blood will more readily block the unwanted growths micro-capillaries. Some or all of the unused components of the hemapheresic separated blood can be returned to the donor, harvested for future use or discarded. The method can also be used periodically to control or treat the condition if no cure is possible. Furthermore, the method can be used on many other chronic conditions which require new blood vessel formation to cause and/or sustain them. Finally, these methods can also be used in combination or conjunction with other therapies, procedures and protocols that seek the same end result for possible synergistic advantages. | 2010-04-08 |
| 20100086531 | METHODS OF MODULATING PROTEIN HOMEOSTASIS, METABOLIC SYNDROME, HEAVY METAL INTOXICATION AND Nrf2 TRANSCRIPTION FACTORS - Phthalazinediones that function as intracellular redox modulators in the redox therapy of certain stressed cells are provided. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions. | 2010-04-08 |
| 20100086532 | CHIMERIC ZINC FINGER RECOMBINASES OPTIMIZED FOR CATALYSIS BY DIRECTED EVOLUTION - The present invention is directed to chimeric recombinases comprising a serine recombinase operatively linked to a zinc finger nucleotide binding domain such that the chimeric recombinase protein catalyzes site-specific recombination at a DNA site specifically bound by the zinc finger nucleotide binding domain. The serine recombinase can be one of several naturally occurring serine recombinases. The invention also includes nucleic acids encoding the chimeric recombinases, vectors including the nucleic acids, host cells transformed or transfected with the vectors, methods of using the chimeric recombinases to carry out recombination, methods of using substrate-linked protein evolution to generate additional chimeric recombinases, methods of using the chimeric recombinases for gene therapy, and pharmaceutical compositions. | 2010-04-08 |
| 20100086533 | LAGLIDADG HOMING ENDONUCLEASE VARIANTS HAVING NOVEL SUBSTRATE SPECIFICITY AND USE THEREOF - A LAGLIDADG homing endonuclease variant having novel substrate specificity, said variant being obtainable by a method comprising: (a) the mutation of at least one amino acid residue of the final C-terminal loop of a parent LAGLIDADG homing endonuclease, with the exclusion of the threonine 140 of I-CreI, b) the selection and/or screening of the variants from step (a) having a pattern of cleaved DNA targets that is different from that of the parent LAGLIDADG homing endonuclease. | 2010-04-08 |
| 20100086534 | STABILIZATION OF PERHYDROLASES - Disclosed herein are enzyme powders comprising a spray-dried formulation of at least one CE-7 esterase, at least one oligosaccharide excipient, and optionally at least one surfactant. Also disclosed herein is a process for producing peroxycarboxylic acids from carboxylic acid esters using the aforementioned enzyme powders. Further, disinfectant and laundry care formulations comprising the peracids produced by the processes described herein are provided. | 2010-04-08 |
| 20100086535 | STABILIZATION OF PERHYDROLASES - Disclosed herein is a method for stabilization of the perhydrolase activity of the CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the mixture of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant and laundry care formulations comprising the peracids produced by the processes described herein are provided. | 2010-04-08 |
| 20100086536 | Method of Increasing Plasmin Activity through Antiplasmin Conversion - Methods for increasing plasmin activity in a patient in need thereof are provided, comprising administering to the patient a therapeutic amount of an agent which binds to α2-antiplasmin at a binding site to increase conversion of cc2-antiplasmin from an inhibitor to a plasmin substrate, thereby increasing plasmin activity in the patient. Also provided are methods for the identification of compounds or molecules that increase plasmin activity, comprising determining whether the compound or molecule binds to a binding site on α2-antiplasmin which increases the conversion of α2-antiplasmin from an inhibitor to a plasmin substrate, wherein the compound or molecule is not an antibody, thereby identifying a compound or molecule which increases plasmin activity. Further provided are pharmaceutical compositions and methods of use thereof for the treatment of myocardial infarction, thrombosis, ischemic stroke, and pulmonary embolism. | 2010-04-08 |
| 20100086537 | POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER - The present invention relates to polynucleotide and polypeptide sequences which are differentially expressed in cancer cells compared to normal cells. The present invention more particularly relates to the use of these sequences in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells. | 2010-04-08 |
| 20100086538 | Antibody Molecules Which Bind to Human IL-17 - The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 2010-04-08 |
| 20100086539 | Method and preparations for the diagnosis and therapy of multiple sclerosis and immune demyelinating polyneuropathy - The subject of the present invention is a method of diagnosing or treatment multiple sclerosis and immune demyelinating polyneuropathy as well as preparations used in these methods. The present invention is applicable in medicine. | 2010-04-08 |
| 20100086540 | CO-CRYSTAL OF ANTIBODY 11F8FAB FRAGMENT AND EGFR EXTRACELLULAR DOMAIN AND USES THEREOF - The present invention relates to co-crystals of antibody 11F8 Fab fragments and the complete extracellular domain of EGFR or isolated domain III of EGFR, and structural coordinates obtained from such crystals. Such coordinates are useful for identifying mimetics that bind to the extracellular domain of EGFR. Such mimetics may, for example, inhibit binding of ligands to EGFR, inhibit activation of EGFR, and/or reduce proliferation of tumor cells. | 2010-04-08 |
| 20100086541 | REGULATION OF AUTOPHAGY PATHWAY PHOSPHORYLATION AND USES THEREOF - The invention relates to polypeptides and proteins known to function in the autophagy pathway that have novel phosphorylation sites. The invention also relates to antibodies specific to these polypeptides and proteins that are phosphorylated or not phosphorylated at novel phosphorylated sites. The invention also relates to methods of producing these antibodies and use of these antibodies in the treatment of diseases related to autophagocytosis. | 2010-04-08 |
| 20100086542 | POTENTIATION OF ERYTHROPOIETIN (EPO) ACTION BY MEMBRANE STEROID RECEPTOR AGONISTS - The present invention relates to the use of membrane steroid receptor agonists as potentiators of the action of erythropoietin (EPO). The present invention also relates to the combined use of membrane steroid receptor agonists and erythropoietin to control apoptosis, proliferation, differentiation, migration and regeneration of cells, in different organs and tissues. Compositions comprising (i) a membrane steroid receptor agonist and (ii) erythropoietin are also provided, as are kits comprising (i) a membrane steroid receptor agonist and (ii) erythropoietin. | 2010-04-08 |
| 20100086543 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH CERAMIDE BIOSYNTHESIS - Provided are a pharmaceutical composition and a method for reducing, preventing, or delaying the development of a biological condition associated with administration of an opioid drug, in particular, tolerance to and/or physical dependence on an opioid drug. The pharmaceutical composition includes an opioid drug, a ceramide biosynthesis inhibitor and a pharmaceutically acceptable carrier. The method of treatment involves administration of an opioid drug and a ceramide biosynthesis inhibitor. Also provided are a method of screening for an agent that reduces, prevents or delays the development of tolerance to and/or physical dependence on an opioid drug as well as compositions comprising a dsRNA for inhibiting ceramide biosynthesis in a cell and a vector for expressing a shRNA for inhibiting ceramide biosynthesis in a cell. | 2010-04-08 |
| 20100086544 | COMPOSITIONS AND METHODS FOR TREATING A NEOPLASM - The present invention relates to compositions and methods for treating neoplasms, including refractory or relapsed neoplasms, using VEGF antagonists. Furthermore, the present invention provides therapy regimens for treating those diseases. | 2010-04-08 |
| 20100086545 | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease - The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease. | 2010-04-08 |
| 20100086546 | Toll-LIke Receptor 4 Deficiency and Downstream Effectors Cause Pulmonary Emphysema - The present invention provides compositions and methods for the detection, treatment, and prevention of emphysema/COPD. Compositions of the present invention comprise TLR4 activators, Nox3 inhibitors, and Cathepsin E inhibitors useful in the treatment or prevention of emphysema/COPD. Cathepsin E is a downstream effector of TLR4, wherein when cathepsin E is overexpressed in lung of an individual, the individual is at higher risk of developing emphysema/COPD. Cathepsin E is further identified as a biomarker useful in the identification of an individual with, or at-risk of developing emphysema/COPD. | 2010-04-08 |
| 20100086547 | METHODS FOR ADMINISTERING ANTI-IL-5 ANTIBODIES - The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, methods are provided for reducing eosinophils in a human in need thereof, which method comprises administering to said human a composition comprising at least one anti-IL-5 antibody, wherein at least one anti-IL-5 antibody provides a mean maximum plasma concentration of said anti-IL-5 antibody of at least about 1.03±0.21 μg/mL, an Area Under the Curve value of at least about 15.5±2.7 μg/day/mL and a serum half-life of about 16.2±2.1 days to about 21.7±2.8 days. | 2010-04-08 |
| 20100086548 | Use of Anti-IL-20 Antibody for Treating Rheumatoid Arthritis and Osteoporosis - Treatment of rheumatoid arthritis and osteoporosis using an anti-IL-20 antibody 7E, and optionally, in combination with an etanercept polypeptide. | 2010-04-08 |
| 20100086549 | Use of Anti-IL-20 Antibody for Treating Stroke - Treatment of stroke with an antibody specific to IL-20, e.g., monoclonal antibody 7E. | 2010-04-08 |
| 20100086550 | ANTICANCER AGENT COMPRISING ANTI-PD-1 ANTIBODY OR ANTI-PD-L1 ANTIBODY - Provided is an anticancer agent which comprises an anti-PD-1 antibody or an anti-PD-L1 antibody as an active ingredient, functioning to reverse the unresponsiveness of iNKT cells in which anergy has been induced by administration with an iNKT cell ligand. The anti-PD-1 or anti-PD-L1 antibody blocks the PD-1/PD-L1-mediated signaling pathway not only to prevent the iNKT cell ligand-induced iNKT cell anergy, but also to reverse the unresponsiveness of already anergic iNKT cells to produce cytokines. In addition, the anti-PD1 or anti-PD-L1 antibody ensures the potent anti-tumor activity of iNKT cells as demonstrated by a significant reduction in the number of metastatic nodules in B16F10 melanoma metastasis models in vivo. Collectively, the anticancer agent can be very useful in the treatment of cancer, particularly metastatic cancer. | 2010-04-08 |
| 20100086551 | ANTIBODY AND USES THEREOF - A method of inhibiting angiogenesis in a group of cells, a tissue or an organ includes administering an antibody molecule or nucleic acid encoding an antibody molecule to the cells, tissue or organ, wherein the antibody molecule specifically binds cathepsin S, but does not inhibit proteolytic activity of cathepsin S. | 2010-04-08 |
| 20100086552 | ALLERGEN-BINDING IGE MONOCLONAL ANTIBODIES AND METHOD FOR PREPARING HYPOALLERGENS - The present invention relates to human IgE antibodies and derivatives thereof, which bind non-continuous planar allergenic epitope, such as in β-lactoglobulin, with high affinity and specificity. The present invention also relates to processes for making and engineering such allergen binding monoclonal antibodies and to methods for using these antibodies and derivatives thereof in the field of immunodiagnostics and immunotherapy. | 2010-04-08 |
| 20100086553 | ANTITUMOR AGENT - To provide a pharmaceutical agent or an antitumor agent useful for the treatment and/or prevention of gastrointestinal cancer, leukemia, pituitary tumor, small cell lung cancer, thyroid cancer, and neuroastrocytoma. The antitumor agent containing, as an active ingredient, a 1,5-benzodiazepine derivative represented by the following formula (1): | 2010-04-08 |
| 20100086554 | METHODS FOR ADMINISTERING ANTI-IL-5 ANTIBODIES - The present invention relates to methods of treating nasal polyposis, in a human, comprising the step of administering to said human in need thereof an effective amount of a composition comprising at least one anti-11-5 antibody wherein said antibody comprises a heavy chain and a light chain. | 2010-04-08 |
| 20100086555 | NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USES THEREOF - The invention relates to antibodies and antigen binding fragments thereof, that bind to hemagglutinin and neutralize infection of at least two different group 1 subtypes or at least two different group 2 subtypes of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection. | 2010-04-08 |
| 20100086556 | USE OF HEMAGGLUTININ OF THE AFRICAN SWINE FEVER VIRUS AS AN ADJUVANT - The invention generally relates to the use of the hemagglutinin (HA) of African swine fever virus (ASFV) as an adjuvant to enhance the immune response against an antigen in a subject. The invention provides a gene construct comprising all or part of the encoding sequence of said HA fused to the encoding sequence of an antigen. The invention is applicable in human and animal health. | 2010-04-08 |
| 20100086557 | Pharmaceutical composition for tumor treatment - The present invention provides pharmaceutical compositions for use in tumor therapy as well as a medical treatment in tumor therapy. The compositions comprise a leukocyte diminishing and/or leukocyte inactivating agent for use in bacterial tumor therapy in combination. Preferably, the leukocyte inactivating or diminishing agents are expressed by the bacteria used for the production of a pharmaceutical composition for bacterial tumor therapy. | 2010-04-08 |
| 20100086558 | Protein Having Prolyl Oligopeptidase Activity, Nucleic Acid Encoding Same and Method for Producing and Using Same - Proteins isolated from | 2010-04-08 |
| 20100086559 | POLYPEPTIDE FORMULATION - The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same. | 2010-04-08 |
| 20100086560 | CHEMOKINES AS ADJUVANTS OF IMMUNE RESPONSE - Dendritic cells play a critical role in antigen-specific immune responses. Materials and Methods are provided for treating disease states, including cancer, infectious diseases, autoimmune diseases, transplantation, and allergy by facilitating or inhibiting the migration or activation of a specific subset of antigen-presenting dendritic cells known as plasmacytoid dendritic cells (pDC). In particular, methods for treating disease states are provided comprising administration of chemokine receptor agonists and antagonists, alone or in combination with a disease-associated antigen, with or without an activating agent. | 2010-04-08 |
| 20100086561 | Th1 vaccination priming for active immunotherapy - The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease. | 2010-04-08 |
| 20100086562 | Use of Platelet Glycopeptide IIIA Epitopes in the Treatment of Immune Thrombocytopenic Purpura - The present invention relates to a composition for treating diseases associated with autoantibodies specific for platelet proteins, in particular autoimmune thrombocytopenic purpura. The composition, comprising an epitope of a platelet protein, treats diseases by tolerisation. | 2010-04-08 |
| 20100086563 | Compositions and Methods for Detection of Antibodies Specific for Anaplasma phagocytophilum (Aph) and Anaplasma platys (Apl) - The invention provides methods and compositions for the detection and treatment of | 2010-04-08 |
| 20100086564 | West Nile Virus Vaccine - The invention provides chimeric flavivirus vaccines against West Nile virus and methods of using these vaccines to prevent or treat West Nile virus infection. | 2010-04-08 |
| 20100086565 | Vectors for expression of hml-2 polypeptides - A nucleic acid vector comprising: (i) a promoter; (ii) a sequence encoding a HML-2 polypeptide operably linked to said promoter; and (iii) a selectable marker. Preferred vectors comprise: (I) a eukaryotic promoter; (ii) a sequence encoding a HML-2 polypeptide downstream of and operably linked to said promoter, (iii) a prokaryotic selectable marker; (iv) a prokaryotic origin of replication; and (v) a eukaryotic transcription terminator downstream of and operably linked to said sequence encoding a HML-2 polypeptide. Vectors of the invention are particularly useful for expression of HML-2 polypeptides either in vitro (e.g. for later purification). Or in vivo (e.g. for nucleic acid immunization). They are well suited to nucleic acid immunization against prostrate tumors. A preferred HML-2 is PCAV, which is located in chromosome 22 at 20.428 megabases (22q11.2). | 2010-04-08 |
| 20100086566 | HIV ADMINISTRATION PROTOCOLS - Administration protocols for a fusion protein, matrix protein and psoralen inactivated HIV based immunogenic composition that induces an immune response to HIV. The immunogenic compositions are based on HIV biologically active fusion peptide, matrix peptide, or psoralen inactivated HIV. The number of doses is 3X. The starting dose for an adult is 1×10 | 2010-04-08 |
| 20100086567 | Botulinum toxin therapy for prevention of anastamotic thrombosis in free tissue transfer - An effective, long lasting, non-systemic drug administration protocol for preventing vascular vasospasm and vessel thrombosis in free tissue transplantation. In a free flap procedure, after the recipient vein and artery (vascular pedicle) are divided, the recipient artery and vein are pretreated with a local injection of | 2010-04-08 |
| 20100086568 | MODIFICATION OF ALLERGENS - The invention relates to a process for modifying allergens to enhance their suitability in immunotherapy. The invention further relates to the modified allergens and pharmaceutical compositions thereof, as well as to their use in immunotherapy. | 2010-04-08 |
| 20100086569 | USE OF A FIRST HOUSE DUST MITE GROUP 2 ALLERGEN FOR TREATING ALLERGY TO A SECOND HOUSE DUST MITE GROUP 2 ALLERGEN - The present invention relates to the use of a Der f 2 allergen composition for the manufacture of a vaccine for preventing or treating allergy to Der p 2, as well as to the use of a Der p 2 allergen composition for the manufacture of a vaccine for treating allergy to Der f 2. | 2010-04-08 |
| 20100086570 | CANCER IMMUNOTHERAPY PREDICTIVE PARAMETERS - The invention relates to a method for predicting the efficacy of a cancer immunotherapy of an individual with respect to clinical benefit, which comprises the following steps: —providing a blood sample of said individual, —(a1) determining the number of lymphocytes in the blood of said individual, and/or (a2) determining the number of neutrophils in the blood of said individual, and —(b1) identifying the individual as having a predictive clinical benefit from the immunotherapy, if the number Of lymphocytes is below or equal to a lymphocyte baseline level of 1.4 to 1.8×10 | 2010-04-08 |
| 20100086571 | METHODS TO DECREASE THE RISK OF METABOLIC SYNDROME POST IMMUNIZATION - This invention contemplates (I) assessing the risk of metabolic syndrome and or one of its component diseases/disorders which is associated with an immunization schedule against one or more infectious diseases, or one or more immunogens which induce protective immunity against infectious diseases, (II) screening one or more potential recipients and identifying at least one human subject who would be expected to be immunized safely with said one or more immunogens or said immunization schedule reflective of the analysis from (I), and (III) immunizing said human against said one or more infectious diseases. | 2010-04-08 |
| 20100086572 | RATIONAL PPI DOSAGE FORMS - The invention herein provides for a continuous release dosage form (which is referred to as “dosage forms”) comprising a continuous release dosage form, which releases PPI in a first release portion directly to the gastric mucosa and a second release portion to provide for sustained plasma levels resulting in increased therapeutic efficacy. | 2010-04-08 |
| 20100086573 | COMPOSITION AND METHOD FOR PREPARING STABLE UNILAMELLAR LIPOSOMAL SUSPENSION - Compositions and methods for producing and using stable transparent to translucent unilamellar liposomal suspensions are described. The suspensions include a liposome preparation having a uniform plurality of unilamellar liposomal particles with a mean particle size between about 50 nm to about 290 nm. The particles are suspended in an external phase composition that has a density between about 0.95 g/cc and about 1.25 g/cc, and that is present in an amount between about 30% to about 75% of the weight of the liposomal suspension. The liposome preparation is formed from an aqueous liposomal solution that includes an oil-soluble composition and a water-soluble composition. The oil-soluble composition is present at a concentration between about 5% to about 33% by weight of the liposomal solution and the water-soluble composition is present at a concentration between about 67% to about 95% by weight of the liposomal solution. | 2010-04-08 |
| 20100086574 | Use of aqueous emulsions in the form of foam for the reloading of textiles - The invention relates to the use of aqueous emulsions and/or dispersions in the form of foam for the reloading of textiles. These aqueous emulsions and/or dispersions contain (a) 0-25% by weight of one or several skin-protecting oils, (b) 0-25% by weight of microcapsules loaded with active ingredients, (c) 0-20% by weight of one or several emulsifiers, (d) 0.1-25% by weight of one or several foam-producing agents, (e) 0-10% by weight of one or several foam stabilizers, and (f) the remainder at 100% by weight of water, with the condition that at least one of the components (a) or (b) must be present in a quantity of more than 0% by weight, and the further condition that the foam must fulfill the following conditions: the foam density is in the range of 50 to 300 g/l and the foam disintegration time is in the range of 2 to 30 min. | 2010-04-08 |
| 20100086575 | BENEFIT AGENT CONTAINING DELIVERY PARTICLE - The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing reduced amounts of benefit agents to be employed. In addition to allowing the amount of benefit agent to be reduced, such particles allow a broad range of benefit agents to be employed. | 2010-04-08 |
| 20100086576 | ANTIMICROBIAL COMPOSITION AND METHODS OF MAKING AND USING SAME - An aqueous composition adapted to kill bacteria in both planktonic and biofilm states is lethal toward a wide spectrum of gram positive and gram negative bacteria as well as other microbes. The composition, which is slightly to moderately acidic, includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. The composition can be applied directly to a site of bacterial growth. Even when the bacteria is in biofilm form, the surfactant component(s) begin to kill the bacteria before the macro-molecular matrix is removed or dislodged from the site. | 2010-04-08 |
| 20100086577 | METHOD AND DEVICE FOR DESTRUCTION OF LICE AND LICE EGGS - A method for treating and killing lice and lice eggs in hair of a person includes the steps of: combing and ironing the hair of the person using a hand-held flat-iron device. The flat-iron device includes a handle having a first arm and a second arm that is pivotally coupled to the first arm at first ends thereof, wherein in an open position, strands of hair are inserted between the first and second arms. The flat-iron device also includes at least one heat conducting plate that is disposed along an inner surface of one of the first and second arms. The plate is operably coupled to a source of heat for controlled heating of the plate to a temperate of at least 130° F. A first edge of the heat conducting plate extends to within 1 millimeter of a first edge of the arm on which the heat conducting plate is disposed. In a closed position, the strands of hair are pinched and held between the two arms in contact with the heated plate resulting in heat being applied to the hair including within a zone that is less than 5 millimeters from a scalp of the person. | 2010-04-08 |
| 20100086578 | FISTULA PLUG COMPRISING ECM - The present invention relates to a temporary composite scaffold comprising discrete ECM particles formed as a fistula plug. We demonstrate that when using scaffolds containing ECM material, higher concentrations of ECM surprisingly do not give better cell morphology. Concentrations lower than 60% (w/w) are sufficient to obtain the best cell morphology and distribution. | 2010-04-08 |
| 20100086579 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE - The present invention provides a device for intracorporeal use including an implant or a temporary device and at least one source of a compound myolimus, or a derivative thereof. The present invention also provides a method of inhibiting cell proliferation by local administration of a therapeutically effective amount of a compound myolimus, or a derivative thereof. Further included in the present invention is a method of treating an ophthalmic condition or disease by administering a therapeutically effective amount of a compound myolimus, or a derivative thereof. | 2010-04-08 |
| 20100086580 | MEDICAL DEVICE WITH CONTROLLABLY RELEASABLE ANTIBACTERIAL AGENT - There is disclosed a medical device, such as a urinary catheter, comprising a substrate material, a hydrophilic surface coating, e.g. comprising polyvinylpyrrolidone (PVP), arranged on at least a part of the surface of said substrate material, and an antibacterial layer comprising oligodynamic metal arranged between the substrate material and the hydrophilic surface coating. Further, the hydrophilic surface coating has a thickness large enough to provide a controlled release of oligodynamic metal ions through the hydrophilic surface coating, such as a thickness when dry that exceeds 3 μm. Hereby, the variation in the release of the oligodynamic metal ions is significantly reduced, enabling an improved control of the release. A corresponding method is also disclosed. | 2010-04-08 |
| 20100086581 | METHOD FOR PURPURA REDUCTION AND PREVENTION - A method for reducing or eliminating skin discoloration caused by purpura or similar conditions uses corticosteroids, particularly glucocorticoids, in a long term cutaneous treatment. A cream, ointment, spray or other means is used to apply a glucocorticoid, for example, hydrocortisone to warmed skin having a red or purple discoloration. Application is continued daily for several months or years to reduce, eliminate and prevent discoloration. | 2010-04-08 |
| 20100086582 | AMORPHOUS ROTIGOTINE TRANSDERMAL SYSTEM - The present invention refers to a transdermal delivery device comprising a backing layer, an adhesive matrix layer comprising a supersaturated concentration of rotigotine substantially in amorphous form within the adhesive matrix, and a release liner. The present invention also refers to a method of preparing an adhesive matrix containing a supersaturated amount of rotigotine substantially in amorphous form. Further, the present invention refers to a method of stabilizing and a method of reestablishing the meta-stable amorphous-drug transdermal system during its manufacturing, storing, shipping and handling process. | 2010-04-08 |
| 20100086583 | LIPID-ANALOGOUS PHOSPHORIC TRIESTERS - The present invention relates to novel phosphoric triesters which comprise apolar lipid structures. | 2010-04-08 |
| 20100086584 | VACCINE COMPOSITIONS OF M2e, HA0 AND BM2 MULTIPLE ANTIGENIC PEPTIDES - The present disclosure generally relates to a composition comprising one or more peptides selected from influenza virus antigenic peptides M2 | 2010-04-08 |
| 20100086585 | Antinuclear antibody utilized as a targeting agent for pharmaceutical compounds used in the treatment of cancer and other diseases - This invention describes a method whereby autoimmune antinuclear antibodies are used as a targeting agent to deliver drug nanoparticles or drug liposomes to the tumor or disease site. The antinuclear antibodies have the propensity to localize in areas of tissue necrosis where dead cells have released their nuclear material into the extracellular environment. Many tumors have areas of necrosis that can be targeted using antinuclear antibody coated drug nanoparticles or liposomes. Similarly, many infectious diseases have areas of necrosis and can also be targeted using antinuclear antibody coated drug nanoparticles or liposomes. Similarly, many immune disorders such as rheumatoid arthritis and osteoarthritis have areas of inflammation where there is cell death, and these inflammatory sites can also be targeted using antinuclear antibody coated drug nanoparticles or liposomes. | 2010-04-08 |
| 20100086586 | Pharmaceutical Composition - A pharmaceutical composition comprising eplerenone having a D90 particle size of between 15-25 microns and further comprising one or more pharmaceutically acceptable excipients. | 2010-04-08 |
| 20100086587 | HARD SHELL CAPSULE FORMULATIONS - Hard shell capsules filled with a normally hygroscopic formulation and a method for producing the same is described. The hard shell capsules are filled with a normally hygroscopic formulation including, for example, an excipient, and optionally an active compound. The water content of the formulation and the hard shell capsule are in equilibration, and the formulation is hydrated by an amount selected to control equilibrium between said formulation and the hard shell capsule, and to provide a structurally stable hard shell capsule. The active compound may be a protein or peptide. | 2010-04-08 |
| 20100086588 | COMPOSITIONS AND METHODS FOR TREATMENT OF BOWEL DISEASES WITH GRANULATED MESALAMINE - Disclosed are methods for treating gastrointestinal disorders, e.g., Crohn's disease, ulcerative colitis, and diverticular disease, with a granulated mesalamine formulation. Some formulations use granulated mesalamine in capsule form. Also included are methods to extend remission of ulcerative colitis by administration of a once-daily dosage of granulated mesalamine. | 2010-04-08 |
| 20100086589 | EXTENDED RELEASE PELLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient. | 2010-04-08 |
| 20100086590 | NOVEL STABLE PHARMACEUTICAL COMPOSITIONS OF CLOPIDOGREL BISULFATE AND PROCESS OF PREPARATION THEREOF - The present invention discloses novel stable oral pharmaceutical compositions comprising the active ingredient Clopidogrel bisulfate and hydrophilic polymers along with pharmaceutically acceptable excipients. Particularly, the said Clopidogrel bisulfate is crystalline Form 1 and the composition additionally comprises of one or more chelating agents and antioxidants. Further the invention relates to a novel process for preparation of stable pharmaceutical compositions wherein the Clopidogrel bisulfate Form I is coated with a hydrophilic polymer thereby providing an increased physical and chemical stability to the composition. | 2010-04-08 |
| 20100086591 | Rapidly Disintegrating Dosage Form - The invention provides a rapidly disintegrating dosage form comprising a partially-coated tablet having at least one elongated groove along its surface, such that a portion of the at least one elongated groove extends beneath the coating. | 2010-04-08 |
| 20100086592 | MODIFIED DOSAGE FORMS OF TACROLIMUS - The present invention provides a modified release dosage form of tacrolimus that releases two or more amount of tacrolimus upon oral administration, the first amount of tacrolimus releases from the immediate release dosage unit substantially immediately within 0-2 hours followed by a time interval ranging from about 1-10 hours during which substantially no amount of tacrolimus is released from the dosage form, after which a second amount of tacrolimus is released wherein said second amount is released from the delayed release dosage unit either immediately e.g. within 0-2 hours or over a period of time ranging from about 2-12 hours from its initial release from the delayed release dosage unit. The dosage form may further comprise additional amount of tacrolimus to provide additional pulse of tacrolimus. The dosage forms of tacrolimus exhibit improved bioavailability and reduced flux or fluctuation over existing composition of tacrolimus. A method of preparing the dosage forms is also described. | 2010-04-08 |
| 20100086593 | DOSAGE FORMS OF BISPHOSPHONATES - Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower gastrointestinal tract of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 2010-04-08 |
| 20100086594 | WATER SOLUBLE REACTIVE DERIVATIVES OF CARBOXY POLYSACCHARIDES AND FIBRINOGEN CONJUGATES THEREOF - The present invention provides water-soluble reactive esters of carboxy polysaccharides and derivatives thereof. The reactive carboxy polysaccharide derivatives are useful per se in aqueous solutions or specifically for the formation of water-soluble covalent fibrinogen conjugates. A preferred conjugate is a hyaluronic acid-fibrinogen conjugate and fibrin adhesive, clot or matrix derived from it. Methods of preparation and methods of use in tissue repair and regeneration are also disclosed. | 2010-04-08 |
| 20100086595 | NON-IONIZABLE HYDROPHOBIC GALENICAL SYSTEM - The present invention concerns a novel hydrophobic galenic system allowing improved masking of the taste of the active ingredients it contains, the stability of said active ingredients and, when applicable, sustained release thereof. The galenic system of the invention consists of lipid particles with no surfactants or emulsifiers, comprising a lipid hydrophobic matrix that is non-ionizable at physiological pH in which the active ingredient(s) are dispersed. This system is suitable for the preparation of pharmaceutical or veterinary compositions, in particular for administration via oral route or via injection. | 2010-04-08 |
| 20100086596 | MICROSPHERES FOR RELEASING AN OCTREOTIDE COMPOUND WITHOUT AN INITIAL TIME LAG - Microspheres for releasing an octreotide compound without an initial time lag include a poly(D,L-lactide-co-glycolide) polymer (PLGA polymer) matrix having a ratio of lactide to glycolide ranging from 80:20 to 90:10 mol %. The polymer has a molecular weight ranging from about 6000 to 16000. The octreotide compound is dispersed in the polymer matrix. The microspheres can be made by forming a dispersed phase by combining the above polymer, dichloromethane, the octreotide compound, methanol and acetic acid. A target loading of the octreotide compound in the dispersed phase ranges from 7 to 12% by weight. Polyvinyl alcohol is dissolved in water to form a continuous phase. The dispersed phase is mixed in the continuous phase to form a microsphere suspension. The dichloromethane, acetic acid, methanol and polyvinyl alcohol are removed from the microsphere suspension. Residual dichloromethane and methanol are removed from the microspheres by washing. | 2010-04-08 |
| 20100086597 | MICROSPHERES FOR THE SUSTAINED RELEASE OF OCTREOTIDE WITH A LOW INITIAL BURST - This disclosure features microspheres and a method of making them. The microspheres are for sustained release of an octreotide compound with a low initial burst, comprising a poly(D,L-lactide-co-glycolide) polymer matrix and an octreotide compound dispersed in the polymer matrix. The microspheres release less than 1% of a total amount of the octreotide compound within 1 hour at 37° C. and pH 7.4. | 2010-04-08 |
| 20100086598 | TRAVERSAL OF NUCLEIC ACID MOLECULES THROUGH A FLUID SPACE AND EXPRESSION IN REPAIR CELLS - Disclosed are methods for use in transferring nucleic acids into cells at a wound site associated with a fluid space. These gene transfer protocols are suitable for use in transferring various nucleic acids into cartilage, cardiac muscle, and other tissues, and have many uses including treating diseases such as arthritis and ischemic heart disease, and promoting wound healing. The invention further disclosed pharmaceutical compositions that may be used in the practice of the invention to transfer the nucleic acid of interest. Such compositions include any multi-partitioned biocompatible matrix in combination with multiple nucleic acids of interest. | 2010-04-08 |
| 20100086599 | ORAL MODIFIED RELEASE FORMULATIONS - This invention is directed to an oral modified release formulation of the phytoestrogen 8-Prenylnaringenin in combination with a progestin, preferably with Drospirenone, and several uses thereof. In another aspect of the invention an oral modified formulation of 8-Prenylnaringenin with an immediately releasing progestin, like Drospirenone, is provided as well as several uses thereof. | 2010-04-08 |
| 20100086600 | Flowable Carrier Matrix - A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site. | 2010-04-08 |
| 20100086601 | Modified Calcium Phosphate Nanoparticle Formation - The present disclosure relates to non-aggregating nanoparticles and their associated methods of preparation. The nanoparticles may have a surface and a size range of 1 nm to 999 nm, along with a zeta potential of −50 to 50 millivolts. A polycation and/or polyanion may be disposed on the nanoparticle surface. In addition, an active ingredient may be encapsulated within the nanoparticles or associated with the polycation or polyanion on the nanoparticle surface. | 2010-04-08 |
| 20100086602 | PHARMACEUTICAL COMPOSITION CONTAINING STATIN-ENCAPSULATED NANOPARTICLE - The present invention provides a novel nanotechnology-based strategy for therapeutic neovascularization. Said statin-loaded nanoparticle allows local delivery of statin and thus improves therapeutic efficacy of several kind of diseases which may treated by statin such as ischemic neovascularization. | 2010-04-08 |
| 20100086603 | COMPOSITION FOR PHOTOPROTECTION - The present invention relates to a method for improving the lifetime of compounds that are prone to photo-degradation by containing the compounds in microcapsules, which have light protecting particles bonded chemically to the capsule walls. In particular, the present invention relates to a microcapsule comprising a biologically active compound inside the microcapsule and light protecting particles which are chemically bonded to the microcapsule wall material; to the use of such a microcapsule; to a process for preparing such a microcapsule; and to surface-modified light protecting particles and their use in such a microcapsule. | 2010-04-08 |
| 20100086604 | ABSORBANT SUPERHYDROPHOBIC MATERIALS, AND METHODS OF PREPARATION AND USE THEREOF - The present invention relates to coated, absorbent, freestanding assemblies comprising inorganic nanowires, articles of manufacture comprising the same, processes of producing the same and methods of use thereof. The assemblies of this invention are useful in various applications, including removal of organics or hydrophobic materials, and waterproofing applications. | 2010-04-08 |
| 20100086605 | MATERIAL, ITEM AND PRODUCTS COMPRISING A COMPOSITION HAVING ANTI-MICROBIAL PROPERTIES - A coating product composition has the general formula AO | 2010-04-08 |
| 20100086606 | Active Agent Loaded Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same - Uniform, rigid, spherical nanoporous calcium phosphate particles that define an internal space and an amount of active agent present in the internal space are provided. Also provided are topical delivery compositions that include the active agent loaded particles, as well as methods of making the particles and topical compositions. The particles and compositions thereof find use in a variety of different applications, including active agent delivery applications. | 2010-04-08 |
| 20100086607 | Self-Assembled Biodegradable Nanoparticles for Medical and Biological Applications - A method for forming a biodegradable composition that self-assembles into nanoparticles is provided. The method includes reacting N,N′-Disuccinimidyl carbonate with hydroxyl end-groups of poly(lactide-co-fumarate) to form a composition comprising succinimide-terminated poly(lactide-co-fumarate). | 2010-04-08 |
| 20100086608 | Methods and Devices for Detecting Binding Events via Zeta-Potential and Pharmacologically Active Compounds and Delivery Systems Identified Thereby - Methods, devices and arrays for measuring a change in zeta-potential of a surface indicative of a binding event are provided. Pharmacologically active compounds and delivery systems for active pharmaceutical ingredients determined to be pharmacologically active or optimized for pharmacological activity or determined to be useful for delivery of the active pharmaceutical ingredient to a target via measurement of a change in zeta-potential of the compound, ingredient or delivery system are also provided. | 2010-04-08 |
| 20100086609 | Methods and Compositions for Delivering Peptides - Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration. The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biological membrane in order to facilitate transport. In one embodiment, insulin is administered via the pulmonary delivery of microparticles comprising fumaryl diketopiperazine and insulin in its biologically active form. This method of delivering insulin results in a rapid increase in blood insulin concentration that is comparable to the increase resulting from intravenous delivery. | 2010-04-08 |
| 20100086610 | VAULT AND VAULT-LIKE CARRIER MOLECULES - A method of using vaults as carrier molecules to deliver one or more than one substance to an organism, or to a specific tissue or to specific cells, or to an environmental medium. A vault-like particle. A method of preventing damage by one or more than one substance to an organism, to a specific tissue, to specific cells, or to an environmental medium, by sequestering the one or more than one substance within a vault-like particle. A method of delivering one or more than one substance or a sensor to an organism, to a specific tissue, to specific cells, or to an environmental medium. According to another embodiment of the present invention, there is provided a method of making vault-like particles, and making vault-like particles comprising one or more than one substance, or one or more than one sensor. | 2010-04-08 |
| 20100086611 | Method for Treating Infectious Organisms Normally Considered to be Resistant to an Antimicrobial Drug - The present invention relates to compositions of submicron- to micron-size particles of antimicrobial agents. More particularly the invention relates to a composition of an antimicrobial agent that renders the agent potent against organisms normally considered to be resistant to the agent. The composition comprises an aqueous suspension of submicron- to micron-size particles containing the agent coated with at least one surfactant selected from the group consisting of: ionic surfactants, non-ionic surfactants, biologically derived surfactants, and amino acids and their derivatives. The particles have a volume-weighted mean particle size of less than 5 μm as measured by laser diffractometry. | 2010-04-08 |
| 20100086612 | COATED CARRIERS - The present invention relates to substantially free flowing powder products as well as preparation thereof. The powder product comprises coated carriers with excellent functional properties. The powder products can be produced in a simple and cost efficient way. | 2010-04-08 |
| 20100086613 | CHITOSAN VEHICLE AND METHOD FOR MAKING SAME - The invention relates to chitosan (CS) vehicles with chitosan nanoparticles, as well as methods for making such chitosan vehicles and for using them to carry a DNA or proteins by forming CS-DNA or CS-protein complexes. The present invention also relates to CS-DNA or CS-protein complexes being useful for transdermal delivery of DNA or protein with a low-pressure gene gun. In another aspect, the present invention also relates to CS-DNA or CS-protein complexes being useful for transcutaneous delivery of a DNA or protein with a skin patch. Further aspects of the present invention relate to methods for making CS-DNA or CS-protein complexes and for using them for diagnostic, therapeutic and biological industrial applications. | 2010-04-08 |
| 20100086614 | NANOPARTICULATED ANESTHETIC COMPOSITION FOR TOPIC USE - The present invention relates to a nanoparticulated anaesthetic composition for topical use in which at least one local anaesthetic agent is encapsulated in polymeric nanoparticles. The present invention also relates to the use of such polymeric nanoparticles comprising at least one local anaesthetic agent in the preparation of an anaesthetic composition for topical application to the skin or mucosa. | 2010-04-08 |
| 20100086615 | AGENT FOR TREATMENT OF PULMONARY DISEASE - To provide a pulmonary disease therapeutic drug exhibiting high efficacy and reduced side effects. | 2010-04-08 |
| 20100086616 | BREAST MILK ETHANOL SCREENING SYSTEM AND METHOD - A test kit detects the presence of a target analyte in a fluid sample. In particular, the test kit includes reagents capable of detecting the target analyte of interest in breast milk. More particularly, the test kit is capable of detecting the presence of alcohol, caffeine, nicotine, drugs of abuse, therapeutic drugs, triglycerides, lactose, capsaicin, and gluten, for example, in breast milk. | 2010-04-08 |
| 20100086617 | ANTIVIRAL FIBER, PROCESS FOR PRODUCING THE FIBER, AND TEXTILE PRODUCT COMPRISING THE FIBER - A fiber which has an excellent effect of inhibiting virus multiplication or eradication (deactivation); a process for producing the fiber; and a textile product comprising the fiber are provided. The method for producing an antiviral fiber comprises bonding a metal ion of a metal having deactivation effect to a virus and poor solubility in water to at least a part of a carboxyl group of the fiber having a cross-linked structure and having a carboxyl group in a molecule of the fiber; and then depositing fine particles of the metal and/or metal compound in the fiber by reduction and/or substitution reaction. | 2010-04-08 |
